With Access Restricted, Aduhelm Appears Poised For A Slow Start

Payers Speak Out At ICER Public Meeting

 
• By Jessica Merrill

Reimbursement, health policy and medical experts predicted a slow rollout ahead for Biogen's new Alzheimer's treatment at a public meeting sponsored by ICER.

Slow launch
Market access is becoming a big issue for Aduhelm • Source: Alamy

More from Neurological

More from Therapy Areas